MTOR and hepatocellular carcinoma: By dividing HCC patients into two groups (n=187 for each group) using the median expression level of FOXH1 as cutoff, we found that mTOR signaling was highly enriched in HCC patients with high level of FOXH1 (Figure 5A and Supplementary Figure 5, p=0.003).